Tag: oncology based in vivo cro market top keyplayers

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Oncology Based In-Vivo CRO Market Size During 2025–2029?

The oncology based in-vivo cro market size has shown significant expansion in recent years. It is anticipated to increase from $1.39 billion in 2024 to $1.5 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.7%. The observed growth during the historical period is primarily due to a greater emphasis on oncology therapeutics, the rising incidence of cancer, the transition towards personalized medicine, the expansion of the pharmaceutical industry, and the requirement for target-specific therapies.

The oncology based in-vivo cro market is projected to experience substantial expansion over the coming years. Its value is expected to reach $2.27 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.9%. This anticipated growth throughout the forecast period stems from factors such as emerging market opportunities, a shift towards immuno-oncology therapies, an increase in oncology clinical trials, advancements in precision medicine, and targeted therapies. Furthermore, key trends identified for this period include regenerative medicine and cell therapies, the increasing demand for faster drug development, the adoption of digitalization and data analytics, a focused emphasis on the tumor microenvironment, and the rising prevalence of biologics and immunotherapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

What Are The Top Growth Drivers Impacting The Oncology Based In-Vivo CRO Market Outlook?

The increasing occurrence of cancer is projected to drive the expansion of the oncology-based in-vivo CRO market in the future. Cancer is defined as a collection of illnesses where unusual cells multiply without control, extending past their normal limits, starting in virtually any bodily organ or tissue, and disseminating to other areas via the blood and lymph systems. The diagnosis and treatment of cancer necessitate advanced drugs and devices, all of which must pass through various preclinical and clinical trials, along with regulatory procedures, prior to their market introduction. An oncology in-vivo CRO is an organization engaged by a sponsor firm to deliver research services, including carrying out full or partial stages of a preclinical in-vivo study (involving testing with living organisms like animals, plants, or entire cells) before the drug or device is tested in humans. Consequently, the rising incidence of cancer has also heightened the need for inventive treatments and therapies, thereby fueling the expansion of the oncology-based in-vivo CRO market. For example, the American Cancer Society, a non-profit organization based in the U.S., reported in April 2024 that approximately 609,000 cancer-related fatalities and 1.9 million new cancer diagnoses occurred in the nation in 2022. Projections suggest an estimated 620,000 cancer deaths for 2024, indicating a slight rise in mortality rates. This growing prevalence of cancer is thus propelling the oncology-based in-vitro CRO market.

What Are The Segment Types Shaping The Oncology Based In-Vivo CRO Market?

The oncology based in-vivo cromarket covered in this report is segmented –

1) By Indication: Blood Cancer; Solid Tumors; Other Indications

2) By Model: Syngeneic Model; Xenograft; Patient Derived Xenograft (PDX); Other Models

3) By Application: Hospitals; Rehabilitation Centers

Subsegments:

1) By Blood Cancer: Leukemia; Lymphoma; Myeloma

2) By Solid Tumors: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Other Solid Tumors

3) By Other Indications: Neuroblastoma; Germ Cell Tumors; Sarcomas; Other Specific Indications

Which Market Trends Are Creating New Opportunities In The Oncology Based In-Vivo CRO Industry?

Leading firms within the oncology-based in vivo CRO market are prioritizing personalized oncology models as a means to secure a competitive edge. These models employ patient-derived xenografts (PDXs) for developing customized treatment approaches, thereby improving the pertinence and effectiveness of preclinical research. An example is Charles River Laboratories, a U.S.-based life sciences company, which introduced its OncoMouse platform in 2022, integrating PDX technology for enhanced precision in tumor modeling. The platform offers high-throughput screening features and real-time observation of tumor progression, facilitating swift evaluation of therapeutic outcomes. Furthermore, it supplies integrated data analytics to refine treatment protocols according to specific patient profiles. Such innovations indicate a movement towards more efficacious and patient-focused methodologies in cancer research.

Which Industry Leaders Are Driving Innovation Across The Oncology Based In-Vivo CRO Market?

Major companies operating in the oncology based in-vivo cro market include Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

How Is Oncology Based In-Vivo CRO Market Demand Varying Across Different Regions?

North America was the largest region in the oncology-based in-vivo CRO market in 2024.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology-based in-vivo CRO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Oncology Based In-Vivo CRO Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp

Browse Through More Reports Similar to the Global Oncology Based In-Vivo CRO Market 2025, By The Business Research Company

Oncology Nutrition Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-nutrition-global-market-report

Community Oncology Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Clinical Oncology Next Generation Sequencing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Oncology Based In-Vivo CRO Market Grown from 2024 to 2025?

The market size of in-vivo CRO that is focused on oncology has experienced substantial growth in the past years. It is projected to escalate from $1.39 billion in 2024 to about $1.5 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 8.0%. This growth over the historical period is linked with an escalating focus on cancer therapeutics, a surge in cancer occurrences, a shift towards individualized medicine, expansion in the pharmaceutical sector, and the increasing need for therapies aimed at specific targets.

What Growth Rate Is Anticipated for the Oncology Based In-Vivo CRO Market in the Coming Years?

The size of the in-vivo contract research organization (CRO) market focused on oncology is anticipated to witness a quick expansion in the years to come. It is projected to increase to “$2.28 billion by 2029, with a compound annual growth rate (CAGR) of 10.9%. This escalation during the forecast period can be ascribed to factors like the surfacing of fresh market prospects, a transition towards immuno-oncology treatment modalities, an increment in oncology clinical trials, the advent of precision medicine, and targeted therapies. Dominant trends expected during this period include the incorporation of regenerative medicine and cell therapies, an increased demand for expedited drug development, the embrace of digitalization and data analytics, a focus on the tumor microenvironment, and a surge in biologics and immunotherapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

Who Are the Leading Companies in the Oncology Based In-Vivo CRO Market?

Major companies operating in the oncology based in-vivo cro market include Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.

What Are the Key Drivers of the Oncology Based In-Vivo CRO Market?

The escalating prevalence of cancer is projected to catalyze the amplification of the oncology-focused in-vivo CRO market’s progress. Cancer, an umbrella term for a collection of diseases where abnormal cells multiply and spread without control, crosses normal barriers, originates almost anywhere within the body’s organs or tissues, and disseminates through blood and lymph systems to other sections of the body. The process of cancer treatment and identification necessitates innovative medications and technologies that must pass through various preclinical studies, clinical tests, and regulatory procedures before introduction to the market. An oncology-focused in-vivo CRO, a firm contracted by a sponsor company, offers services like executing complete or partial stages of running an in-vivo preclinical study. This involves testing on living entities, such as animals, plants, or cells, prior to the trial of the drug or device on humans. The increasing cancer rates have led to a surge in demand for innovative treatments, thus propelling the growth of the oncology-based in-vivo CRO market. For example, in April 2024, The American Cancer Society, a US-based non-profit organization, reported approximately 609,000 cancer-related fatalities and around 1.9 million fresh cancer cases diagnosed within the country in 2022. Predictions suggest nearly 620,000 cancer deaths, marking a mild escalation in mortality rates for 2024. Therefore, the escalating prevalence of cancer is fueling the development of the oncology-based in-vitro CRO market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp

What Are the Key Market Segments in the Oncology Based In-Vivo CRO Industry?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Hospitals, Rehabilitation Centers

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Solid Tumors

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas, Other Specific Indications

What Are the Latest Trends in the Oncology Based In-Vivo CRO Market?

Leading organizations in the oncology-focused in vivo CRO market are honing in on personalized cancer models to secure a competitive edge. These tailor-made oncology models employ patient-derived xenografts (PDXs) to devise treatment plans that fortify the significance and effectiveness of preclinical investigations. For example, Charles River Laboratories, an American life sciences firm, rolled out its OncoMouse platform in 2022, harnessing the power of PDX technology for more precise tumor simulation. This platform is equipped with high-capacity screening capabilities and live tracking of tumor development, facilitating swift evaluation of treatment outcomes. Moreover, it offers comprehensive data analytics to refine treatment methods, taking into account individual patient data. These progressive steps mark a transformation towards more efficient, patient-focused methods in cancer study.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

What Are the Key Regional Markets in the Oncology Based In-Vivo CRO Industry?

North America was the largest region in the oncology-based in-vivo CRO market in 2024.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology-based in-vivo CRO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10521

This Report Delivers Insight On:

1. How big is the oncology based in-vivo cro market, and how is it changing globally?

2. Who are the major companies in the oncology based in-vivo cro market, and how are they performing?

3. What are the key opportunities and risks in the oncology based in-vivo cro market right now?

4. Which products or customer segments are growing the most in the oncology based in-vivo cro market?

5. What factors are helping or slowing down the growth of the oncology based in-vivo cro market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the oncology based in-vivo cro industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has the Oncology Based In-Vivo CRO Market Growth Performance Trended Historically, And What Lies Ahead?

The market size of the in-vivo cro specialized in oncology has experienced significant growth in the past years. It is projected to expand from $1.39 billion in 2024 to $1.5 billion in 2025, with an 8.0% compound annual growth rate (CAGR). This growth during the historical period is due to factors such as heightened attention towards oncology treatments, the increasing prevalence of cancer, a shift towards personalized medication, the growth of the pharmaceutical industry, and the demand for therapies targeting specific conditions.

The value of the oncology-focused in-vivo CRO market is anticipated to escalate swiftly in the immediate future. Predictions suggest it will elevate to “$2.28 billion by 2029, with a compound annual growth rate (CAGR) of 10.9%. This surge in the upcoming period is speculated to be due to the advent of new market prospects, shift towards immuno-oncology treatments, increase in oncology clinical trials, precision medicine, and targeted therapies. The forecast period also anticipates significant trends such as the use of regenerative medicine and cell therapies, desire for expedited drug development, digitalization and data analytics, emphasis on tumor microenvironment, and ascend in biologics and immunotherapies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

What are the Fundamental Drivers and Innovations Shaping the Oncology Based In-Vivo CRO Market?

The rising incidence of cancer is anticipated to fuel the expansion of the oncology-based in-vivo CRO market. Cancer is a collection of diseases characterized by the uncontrolled division of abnormal cells that exceed their normal limits, can develop in virtually any organ or tissue, and can spread to other parts of the body via the blood and lymph systems. The treatment and diagnosis of cancer necessitate the development of novel drugs and devices, which must undergo various preclinical trials, clinical trials, and regulatory procedures before they can be introduced into the market. An oncology in-vivo-based CRO is a company that a sponsor company hires to provide research services, such as carrying out all or some of the steps involved in conducting a preclinical in-vivo study (testing on living organisms like animals, plants, or whole cells) prior to the trial of the drug or device in humans. As cancer becomes more prevalent, the demand for new treatments and therapies is also rising, stimulating the growth of the oncology-based in-vivo CRO market. For example, according to the American Cancer Society, a non-profit organization in the USA, approximately 609,000 cancer-related deaths and 1.9 million new cancer cases were reported in the country in 2022. An estimated 620,000 cancer deaths are expected, representing a slight increase in mortality rates in 2024. The increasing incidence of cancer is prompting the expansion of the oncology-based in-vitro CRO market.

How Is the Oncology Based In-Vivo CRO Market Segmented?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Hospitals, Rehabilitation Centers

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Solid Tumors

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas, Other Specific Indications

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp

Which Regions Are Driving the Next Phase of the Oncology Based In-Vivo CRO Market Growth?

North America was the largest region in the oncology-based in-vivo CRO market in 2024.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology-based in-vivo CRO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Trends Are Shaping the Future of the Oncology Based In-Vivo CRO Market?

Significant players in the in vivo CRO market for oncology are pivoting towards personalized oncology models in order to maintain a competitive edge. These models leverage patient-derived xenografts (PDXs) to develop customized treatment plans, thereby improving the significance and effectiveness of preclinical studies. As an illustration, Charles River Laboratories, a life sciences firm based in the U.S., unveiled its OncoMouse platform in 2022. This platform employs PDX technology for enhanced tumor modeling accuracy. Included in its features are high-throughput screening functions and real-time tumor growth tracking, facilitating swift evaluations of therapeutic reactions. It also offers consolidated data analytics to fine-tune treatment guidelines according to each patient’s unique profile. These progressions indicate a move towards more efficient, patient-oriented approaches in the field of cancer research.

View the full report here:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

How Is the Oncology Based In-Vivo CRO Market Defined and What Are Its Core Parameters?

An oncology-based in-vivo contract research organization (CRO) refers to a company hired by another company to perform complete or partial steps of running a preclinical in-vivo study (testing or with living organisms such as animals, plants, or whole cells), such as designing, managing, monitoring, and analyzing in-vivo preclinical results for oncology drugs or devices.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10521

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers Contributing to the Growth and Expansion of the Oncology Based In-Vivo CRO Market?

The escalating incidence of cancer is predicted to fuel the expansion of the oncology-based in-vivo CRO market in the future. Cancer is characterized as a collection of diseases where abnormal cells multiply uncontrollably, exceed their normal limits, originate from almost any tissue or organ in the body, and distribute to other regions of the body via the blood and lymph systems. The treatment and detection of cancer necessitate innovative pharmaceuticals and equipment, which go through various preclinical trials, clinical trials, and regulatory procedures before they are introduced to the market. An oncology in-vivo-based CRO is a firm engaged by a sponsor corporation to provide research services such as conducting complete or partial steps of managing a preclinical in-vivo study (testing on living organisms like animals, plants, or entire cells) prior to the drug or device being tested on humans. With the rising incidence of cancer, the need for new treatments and therapies has also escalated, propelling the oncology-based in-vivo CRO market forward. For example, in April 2024, it was reported by the American Cancer Society, a non-profit organization based in the US, that about 609,000 deaths from cancer and 1.9 million new cases of cancer were detected in the country in 2022. Approximately 620,000 cancer-related deaths are projected, suggesting a slight increase in mortality rates in 2024. This increasing incidence of cancer is stimulating the growth of the oncology-based in-vitro CRO market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

#How Does the ProjectedOncology Based In-Vivo CRO Market Growth Compare Over the Forecast Period?

In recent years, the size of the oncology in-vivo CRO market has significantly expanded. Its growth is forecasted to go from $1.39 billion in 2024 to $1.5 billion in 2025, with a compound annual growth rate (CAGR) of 8.0%. This historic growth can be credited towards an increased emphasis on oncology treatments, a rise in cancer incidents, a move to more personalized healthcare, the expansion of the pharmaceutical sector, and the need for therapies that target specific health issues.

Anticipated to gain quick momentum over the upcoming years, the in-vivo CRO market specializing in oncology is predicted to escalate to a value of “$2.28 billion by 2029, with a compound annual growth rate (CAGR) of 10.9%. The projected growth within this timeframe can be ascribed to emerging market possibilities, a transition towards immuno-oncology treatment methods, an increase in oncology-based clinical trials, precision medicine, and targeted therapeutic approaches. Within the forecast period, key trends include a surge towards regenerative medicine and cell therapies, the need for expedited drug development, the adoption of data analytics and digitalization, a focus on the tumor microenvironment a, and a growing interest in biologics and immunotherapies.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10521

What New Market Trends Are Reshaping theOncology Based In-Vivo CRO Market and Its Opportunities?

Leading firms in the oncology-centric in vivo CRO market are leveraging personalized oncology models to achieve an edge over competitors. These models use patient-derived xenografts (PDXs) to develop custom treatment plans, thereby improving the significance and efficiency of preclinical research. For instance, in 2022, U.S.-based life sciences firm, Charles River Laboratories, introduced its OncoMouse platform that includes PDX tech for superior tumor modeling. This platform offers a high-capacity screening feature and real-time tracking of tumor development, facilitating quick evaluation of treatment responses. Moreover, it incorporates integrated data analytics to fine-tune treatment protocols according to the unique profiles of each patient. Such progress implies a move towards more potent and patient-focused methodologies in cancer studies.

Who Are the Leading Market Players Fueling Growth in the Oncology Based In-Vivo CRO Market Trend?

Major companies operating in the oncology based in-vivo cro market include Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

How is the Global Oncology Based In-Vivo CRO Market Segemented?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Hospitals, Rehabilitation Centers

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Solid Tumors

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas, Other Specific Indications

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp

Which Geographics are Influencing the Growth of the Oncology Based In-Vivo CRO Market?

North America was the largest region in the oncology-based in-vivo CRO market in 2024.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology-based in-vivo CRO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Gobal Oncology Based In-Vivo CRO Maret 2025, By The Business Research Company:

Oncology Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-devices-global-market-report

Oncology Molecular Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-molecular-diagnostics-global-market-report

Community Oncology Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the oncology based in-vivo cro market grown in recent years?

The in-vivo CRO market, primarily focused on oncology, has seen robust growth of late. Expanding from a size of $1.39 billion in 2024 to a projected $1.5 billion in 2025, it promises a compound annual growth rate (CAGR) of 8.0%. This upward trend in the historical period can be traced back to factors such as a heightened emphasis on oncology treatments, a rising number of cancer cases, a shift towards individualized healthcare, the prospering pharmaceutical industry, and the rising demand for therapies targeted at specific ailments.

How is the oncology based in-vivo cro market size expected to evolve during the forecast period?

The size of the in-vivo CRO market, primarily focused on oncology, is projected to undergo substantial expansion in the coming few years, reaching “$2.28 billion by 2029” with a Compound Annual Growth Rate (CAGR) of 10.9%. Factors contributing to this expansion during the forecasted period include burgeoning market prospects, the transition towards immuno-oncology treatments, an increase in oncology-related clinical trials, precision and targeted therapies. Regenerative and cell therapies, the need for expedited drug development, the integration of digitalization and data analytics, attention to the tumor microenvironment and the growth in biologics and immunotherapies are predicted to dominate trends during the forecast period.

Get your oncology based in-vivo cro market report here!

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

Which key drivers are propelling the oncology based in-vivo cro market’s growth?

The surge in cancer instances is anticipated to boost the growth of the oncology-based in-vivo CRO market. Cancer is a collection of diseases characterized by unrestricted cell division that can arise from any organ or tissue and spread throughout the body via the blood and lymph systems. The development of novel drugs and devices for diagnosing and treating cancer undergoes numerous preclinical trials, clinical trials, and regulatory processes before they are commercially available. An oncology-based in-vivo CRO is a research services firm employed by a sponsor company to perform all or portions of a preclinical in-vivo study before testing a drug or device on humans. The surge in cancer prevalence has amplified the desire for innovative medical treatments, enhancing the oncology-based in-vivo CRO market’s growth. As an example, in April 2024, the American Cancer Society, an American nonprofit organization, reported approximately 609,000 cancer fatalities and 1.9 million new cancer diagnoses in 2022. Around 620,000 cancer deaths are projected in 2024, indicating a minor rise in mortality rates. This rise in cancer occurrences is the driving force behind the expansion of the oncology-based in-vitro CRO market.

What are the market segments in the oncology based in-vivo cro industry?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Hospitals, Rehabilitation Centers

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Solid Tumors

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas, Other Specific Indications

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

Which leading companies are shaping the growth of the oncology based in-vivo cro market?

Major companies operating in the oncology based in-vivo cro market include Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.

What key trends are currently impacting the oncology based in-vivo cro market’s development?

In a bid to gain an edge over competitors in the oncology-centric in vivo CRO market, leading companies are turning to personalized oncology models. By using patient-derived xenografts (PDXs), these models allow for the creation of bespoke treatment plans, which amplifies the pertinence and effectiveness of preclinical studies. An example of this is Charles River Laboratories, a life sciences company based in the U.S. that in 2022 unveiled its OncoMouse platform. PDX technology is utilized within the platform for improved precision in tumour modelling. The platform also offers large scale screening capabilities and continuous monitoring of tumour growth, which permits swift evaluations of therapeutic reactions. Furthermore, it employs integrated data analytics for the calibration of treatment protocols that accord with individual patient characteristics. These developments indicate a progression towards more effective, patient-focused method in cancer research.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10521

Which geographic areas are influencing the growth of the oncology based in-vivo cro market?

North America was the largest region in the oncology-based in-vivo CRO market in 2024.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology-based in-vivo CRO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Oncology Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-devices-global-market-report

Oncology Molecular Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-molecular-diagnostics-global-market-report

Community Oncology Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: